More news

More news

Teruna Siahaan Awarded A NIH R01

Teruna Siahaan, Aya and Takeru Higuchi Distinguished Professor of pharmaceutical chemistry has been awarded a NIH R01 grant.  Dr. Siahaan's project title is  "Novel Method to Enhance Drug Delivery to the Brain."

Orozco, CBID Research Project Leader, Finds Gene that Enhances Anti-Viral Immunity

Robin Orozco, an assistant professor of Molecular Biosciences at the University of Kansas, has unveiled new research that explores how a common mutation in the human population changes immune response during a virus infection. Dr.

Siahaan and Fehr recognized as 2023 KU innovators

KU and its medical center are filled with great innovators striving to find creative solutions for the problems facing our world. Today, the KU Center for Technology Commercialization wants to thank all members of KU's research community for their creativity and ingenuity.

Hefty elected to NAIPI National Committee

Congratulations to Dr.

Lynn Hancock Awarded Newest CBID Pilot Project

Lynn Hancock, Associate Professor, Department of Molecular Biosciences, University of Kansas, is the new recipient of a CBID pilot project award.  Dr. Hancock's project title is “Glycobiology at the interface of the host-microbe interaction."

Davido Granted $289,300 by NIH

David Davido, Professor of Molecular Biosciences, has been awarded an NIH supplement grant.  This one year award totals $289,300 for Identifying Novel Inhibitors of HSV-2 ICP0.

New Core Lab Enhances Infectious Disease Research at KU

 A new core laboratory at the University of Kansas will enhance the speed, quantity and quality of research into infectious diseases, neurological disorders, cancer and immunology.

Grant Will Fund Research Into Antibiotic Resistance

Joanna Slusky, Associate Professor in the Department of Molecular Biosciences at the University of Kansas, received a four-year grant from the National Institute of General Medical Sciences with a total cost of $1,244,968.

New Grasp of Key COVID-19 Protein May Lead to a Live-Attenuated Vaccine Effective Against More Variants For Longer

Research from the University of Kansas just published in Proceedings of the National Academy of Sciences could hasten development of a new class of vaccines aimed at SARS-CoV-2, the virus that causes COVID-19.

Fehr, CBID Faculty Recruit, Published New PNAS Article

Congratulations to Dr. Anthony Fehr, Molecular Biosciences, for his most recent publication.

Media Contacts

Shelley Sandberg
Program Manager